- Home
- PYPD vs NRXP Comparison
PYPD vs NRXP Comparison
Compare PYPD & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- NRXP
- Stock Information
- Founded
- PYPD 2008
- NRXP 2015
- Country
- PYPD Israel
- NRXP United States
- Employees
- PYPD N/A
- NRXP N/A
- Industry
- PYPD Medical/Dental Instruments
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- NRXP Health Care
- Exchange
- PYPD Nasdaq
- NRXP Nasdaq
- Market Cap
- PYPD 30.1M
- NRXP 51.3M
- IPO Year
- PYPD 2020
- NRXP N/A
- Fundamental
- Price
- PYPD $2.74
- NRXP $2.07
- Analyst Decision
- PYPD Strong Buy
- NRXP Strong Buy
- Analyst Count
- PYPD 2
- NRXP 3
- Target Price
- PYPD $10.50
- NRXP $31.67
- AVG Volume (30 Days)
- PYPD 13.5K
- NRXP 225.8K
- Earning Date
- PYPD 02-12-2025
- NRXP 03-27-2025
- Dividend Yield
- PYPD N/A
- NRXP N/A
- EPS Growth
- PYPD N/A
- NRXP N/A
- EPS
- PYPD N/A
- NRXP N/A
- Revenue
- PYPD N/A
- NRXP N/A
- Revenue This Year
- PYPD N/A
- NRXP N/A
- Revenue Next Year
- PYPD $4,820.00
- NRXP N/A
- P/E Ratio
- PYPD N/A
- NRXP N/A
- Revenue Growth
- PYPD N/A
- NRXP N/A
- 52 Week Low
- PYPD $2.37
- NRXP $1.10
- 52 Week High
- PYPD $5.50
- NRXP $7.20
- Technical
- Relative Strength Index (RSI)
- PYPD 42.48
- NRXP 37.73
- Support Level
- PYPD $2.82
- NRXP $1.84
- Resistance Level
- PYPD $2.99
- NRXP $2.28
- Average True Range (ATR)
- PYPD 0.22
- NRXP 0.21
- MACD
- PYPD -0.02
- NRXP -0.03
- Stochastic Oscillator
- PYPD 0.00
- NRXP 23.49
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.